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Abstract
Objective: Low levels of IGF-binding protein 1 (IGFBP1) are associated with metabolic syndrome and
predict diabetes development in men. The aim of this study was to determine the levels of IGFBP1 in
women who later develop diabetes, in relation to abdominal obesity, and to compare these levels with
those of men.
Methods: IGFBP1 levels were determined at baseline and after 8 years in a case–control, prospective
study of Swedish women aged 35–56 years. Individuals with normal oral glucose tolerance test
(OGTT) who developed abnormal glucose regulation (nZ240) were pair matched to controls for age
and family history of diabetes and also compared to men of the same age (nZ355).
Results: Low fasting IGFBP1 and increased waist measurement predicted development of diabetes in
women (nZ60; odds ratio (OR) 70, 95% conﬁdence interval(CI) 8–661, lowest tertile and OR 27, 95%
CI 5–141, highest tertile). In women developing diabetes, baseline IGFBP1 levels were lower than
expected for fasting insulin values, were associated with impaired suppression after OGTT and
increased during 8 years despite an increase in fasting insulin. All individuals in the highest tertile for
waist and with %40% suppression of IGFBP1 developed diabetes within 8 years. Circulating IGFBP1
concentrations were higher in women compared to men. Women and men who developed diabetes had
a similar degree of abdominal obesity, corrected for height.
Conclusions: We conclude that low IGFBP1 and elevated waist measurement predict diabetes
development and that IGFBP1 production is suppressed by a novel factor(s) in women developing
diabetes. Increasing levels of IGFBP1 during the emergence of diabetes in men and women suggest the
emergence of hepatic insulin resistance.
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Introduction
Insulin-like growth factor-binding protein 1 (IGFBP1) is
an inhibitor of IGF actions on metabolism and growth.
Circulating concentrations are determined largely by
the action of insulin on its hepatic transcription (1).
Low levels of IGFBP1 are associated with the metabolic
syndrome and cardiovascular disease in cross-sectional
studies (2–4), and predict ischaemic heart disease
mortality (5). In a population study of Swedish men
with normal glucose tolerance (NGT), we found that
low levels of IGFBP1 predicted the development of
abnormal glucose regulation 10 years later (6). During
the development of diabetes however, IGFBP1 levels
increased so that the regression line of IGFBP1 on
insulin was above that of controls, suggesting decreased
hepatic insulin sensitivity.
There are gender differences in the prevalence and
consequences of diabetes. Although the prevalence is
greater in men, women with diabetes are more likely
to be obese (7, 8) and are reported to have a greater
risk of cardiovascular disease (9, 10). Since the most
effective management strategy is likely to target
prevention, predictive markers may help identify
women at risk. In cross-sectional studies, IGFBP1
has been identiﬁed as a marker of hyperinsulinaemia
in obese postmenopausal women, both in the absence
(11) and presence (12) of diabetes. The aims of this
study were to compare the patterns of IGFBP1
concentrations in women with and without abnormal
glucose regulation to those in men, and to determine
whether IGFBP1 is also a predictive marker of
abnormal glucose regulation in women. We made a
novel observation that IGFBP1 concentrations are
lower than expected for the insulin levels in women
who later develop diabetes, suggesting a novel
inhibitor of IGFBP1 production.
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Study population
The study population consists of participants in an
epidemiological survey, the Stockholm Diabetes Preven-
tion Programme (SDPP) (13). Individuals aged 35–56
years without known diabetes were recruited. The men
were invited to participate in baseline studies earlier
than the women, and were invited to follow-up studies
at 10 years. The women were followed up at 8 years.
Baseline and follow-up studies consisted of a ques-
tionnaire covering lifestyle factors, a health exami-
nation and an oral glucose tolerance test (OGTT). The
presence of menstrual bleeding was self-reported. Blood
samples were taken after an overnight fast and 2 h after
ingestion of 75 g glucose.
Individuals were categorized after OGTT according to
the 1999 WHO criteria (14). Diabetes was deﬁned as a
fasting plasma glucose of R7.0 mmol/l and/or 2-h
glucose of R11.1 mmol/l. Impaired glucose tolerance
(IGT) was deﬁned as a 2-h plasma glucose of
7.8–11.0 mmol/l and fasting values of !6.1 mmol/l,
while impaired fasting glucose (IFG) was a fasting glucose
of 6.1–6.9 mmol/l and 2-h glucose of !7.8 mmol/l.
Those with a fasting glucose of 6.1–6.9 mmol/l and 2-h
value of 7.8–11.0 mmol/l were deﬁned as having
combined glucose intolerance (IFGCIGT). The WHO
classiﬁcation of obesity based on body mass index (BMI)
was used (15).
The population was enriched for family historyof type
2 diabetes (FHD) and was at baseline present in about
50% of participants. FHD was deﬁned as known diabetes
with an onset above 35 years in at least one ﬁrst-degree
relative or at least two second-degree relatives.
The present study is an incident case–control study.
We selected individuals with NGT at baseline who
developed abnormal glucose tolerance at follow-up. In
this study, men and women were the same age at the
time of follow-up. Details of selection for men have been
described previously (6). In women undergoing baseline
assessment, a normal OGTT was found in 2397 women
with and 2153 women without FHD (Fig. 1). After 8
years, 4365 women not having type 2 diabetes at
baseline and still living in the same area were invited to
participate in a follow-up study, and 3329 women
accepted (76%).
The study group comprised 240 women who had
NGT at baseline and abnormal glucose regulation at
follow-up. There were 35 women diagnosed with
diabetes on OGTT at follow-up, and in 25 women, a
diagnosis was made by a physician during the 8-year
period. Two women in the latter group had an OGTT in
the follow-up study. There were eight women taking
oral hypoglycaemic agents and ﬁve women on insulin
therapy. At follow-up, 119 women were diagnosed with
IGT, 41 women with IFG and 20 women with IFGCIGT.
The groups developing IFG and IFGCIGT were
combined for statistical analysis. The controls were
pair matched to cases by random selection of 240
individuals from the group of 2863 women with NGTat
baseline and at follow-up, within FHD and age.
Anthropomorphic measurements were not matched in
order to determine the impact of these variables. There
was a history of gestational diabetes mellitus in 6.7% of
cases and 2.9% of controls. As previously described (6),
there were 355 men with abnormal glucose tolerance;
107 men with type 2 diabetes, 122 men with IGT, 79
men with IFG and 47 men with IFGCIGT. There were
355 male controls, pair matched from the group with
NGT at baseline and at follow-up, within FHD and age.
The study was approved by the Ethics Committee of
Karolinska University Hospital, and was carried out in
accordance with the Declaration of Helsinki. All
participants gave informed consent.
Postal questionnaire to all women aged 35–65 years,
residing within four municipalities in Stockholm
n = 19416
Total responders, 85%
n = 16481
8178 excluded*
(50%)
FHD+
n = 3583
FHD–
n = 4296
Random sample
n = 3497
NGT
FHD+: 2397
FHD–: 2153
IGT
FHD+: 88
FHD–: 31
IFG
FHD+: 32
FHD–: 9
T2DM
FHD+: 50
FHD–: 10
IGT, IFG, IGT+IFG
FHD+: 140
FHD–: 68
Health examination,
including OGTT
NGT
FHD+: 1643
FHD-: 1220
63 T2DM (1.3%)
not invited to
follow-up
IFG+IGT
FHD+: 16
FHD–: 4
Abnormal
glucose
tolerance
Excluded
from present
study
8-years, invited to follow-up health
examination, including OGTT.
Total responders 3205
8-years, invited to follow-up
examination and OGTT.
Total responders 124
Baseline study:
Follow-up study:
GDM
n = 424
466 excluded**
Figure 1 Study design: selection and follow-up of women in the
Stockholm Diabetes Prevention Programme. The groups from
which the present study population was derived were categorized
according to 1999 WHO criteria and are shown in bold type. FHDC,
family history of diabetes; FHDK, no family history of diabetes;
GDM, history of gestational diabetes; T2DM, type 2 diabetes
mellitus. *Exclusion criteria: already known diabetes (1.5%),
unclear FHD (28.5%), insufﬁcient FHD according to inclusion
criteria (9.9%), foreign origin (7.6%), moved or deceased (2.0%).
**Subjects aged 35–44 years born in the last third of each month
were excluded for ﬁnancial reasons.
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Serum IGFBP1 was measured using an in-house RIA
with intra- and inter-assay coefﬁcient of variation (CV)
values of 3 and 10% respectively (16). Samples from the
same individual from the OGTT at baseline and at
follow-up were analysed in the same assay. We have
previously conﬁrmed the stability of IGFBP1 after long-
term storage (6). IGF1 was measured in serum by RIA
after acid–ethanol extraction and cryoprecipitation, and
using des(1–3)IGF1 (17). Intra- and inter-assay CV
values were 4 and 11% respectively. Samples from the
same individual were measured in the same assay.
Venous serum glucose was assayed using the glucose
oxidase method (Yellow Springs Glucose Analyzer,
Yellow Springs, OH, USA) and immunoreactive insulin
by in-house assay, as previously described (18). Since
the insulin assays were performed 8 years apart, we
reanalysed baseline samples stored at K20 8C from
individuals with NGT at baseline and at follow-up. The
regression line was
10log(y)Z0.20C0.942
10log(x)
(nZ114; rZ0.953, P!0.001), where x is the original
measurement and y is the value measured after 5–8
years in storage.
Data analysis
Results presented in the tables and ﬁgures are mean
G95% CIs. We have previously described the waist
2:
height ratio (waist measurement in cm/10)
2/(height in
m!10), Wa
2HtR) in the men in this study, which we
used to abolish the effect of height and allow
comparisons between groups (6). The dependence of
waist on height was conﬁrmed in the women (rZ0.14,
PZ0.003, whole group at baseline). The relationship
with height was abolished when Wa
2HtR was used
(rZ0.01, PZ0.854). Serum IGFBP1, IGF1 and insulin,
and Wa
2HtR values were log transformed before
analysis. Differences between baseline and follow-up
were analysed by paired Student’s t-tests. When
continuous variables were compared between two or
more independent groups, unpaired t-test or ANOVA,
and Scheffe’s post hoc test, was used.
Linear regression analysis was used to examine the
relationship between IGFBP1 and other variables.
Analysis of covariance was used to investigate difference
between regression lines; and also when analysing
differences in IGFBP1 between groups, controlling for
the effect of insulin (mean values of IGFBP1 were then
computed at the mean of insulin). Forward stepwise
regression analysis was performed for selection of
independent predictor variables to IGFBP1.
Conditional logistic regression was performed to
calculate odds ratios (ORs) and 95% CIs. Variables were
categorized in tertiles according to their distribution
within the respective groups, among cases and their
respective controls. The lowest tertile (for glucose,
insulin, IGF1, BMI and Wa
2HtR) or the highest tertile
(forIGFBP1)wasusedasthereferenceinthecalculation.
Statistical analyses were performed using SAS version
9.2 (SAS Institute, Cary, NC, USA) and Statistica
StatSoft version 8.0 (Tulsa, OK, USA). Statistical
signiﬁcance was set at !0.01, to take into account
the repeated comparisons.
Results
Control women: comparison of variables at
baseline and at follow-up
Baseline and follow-up data for the whole control group
are shown in Table 1. Although the women had NGT at
baseline and at follow-up, fasting and 2-h glucose
values increased during the 8-year study period. There
was a 1.8 kg gain in weight, and waist measurement
increased by 5 cm. When waist was corrected for height
(Wa
2HtR), there was a 12% increase over the 8-year
study period (95% CI 10–14, P!0.001). There was a
fall in IGF1 concentrations.
Fasting and 2-h insulin concentrations increased
at follow-up, compared to baseline; and fasting
(f)-IGFBP1 level declined signiﬁcantly. There was an
inverse relationship between f-IGFBP1 and f-insulin
both at baseline (rZK0.40, P!0.001) and at follow-
up (rZK0.44, P!0.001). There were also inverse
relationships between f-IGFBP1 and IGF1 (rZK0.38,
P!0.001 at baseline and rZK0.32, P!0.001
at follow-up) and between f-IGFBP1 and Wa
2HtR
(rZK0.35, P!0.001 at baseline and rZK0.38,
P!0.001 at follow-up). In multiple regression analysis,
31% of the f-IGFBP1 variation at baseline could be
accounted for by these three variables (P!0.001).
Women developing abnormal glucose
regulation: variables at baseline
Baseline data for the women having type 2 diabetes at
follow-up are shown in Table 2, and those developing
IFG/IFGCIGT or IGT are shown in Supplementary
Tables 1 and 2, see section on supplementarydata given
at the end of this article respectively. Women who
developed diabetes weighed more than controls
matched for FHD and age, and had higher BMI values
and elevated Wa
2HtR. They had fastingand 2-h IGFBP1
levels that were lower, and fasting and 2-h insulin
values that were higher at baseline compared to
controls. Furthermore, the regression line of f-IGFBP1
on f-insulin was signiﬁcantly below that of the matched
control group (Fig. 2a), so that the levels of IGFBP1 in
relation to insulin were on average 70% of the levels in
controls (P!0.001). At baseline, 26% of the f-IGFBP1
variation in the diabetes group at baseline could be
accounted for by the variable Wa
2HtR (P!0.001) and,
in multiple regression analysis, this was increased to
31% by the addition of IGF1 (PZ0.024) and to 34%
with insulin (PZ0.080). Notably, IGFBP1 was less
suppressed following 75 g oral glucose compared with
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suppression of IGFBP1 was related to the f-IGFBP1 levels
(Fig. 3a).
Women developing IGT or IFG/IFGCIGT had
f-IGFBP1 and 2-h IGFBP1 levels at baseline that were
lower than pair-matched controls (IGT: f-IGFBP1
30 mg/l, 95% CI 27–33, P!0.001; 2-h IGFBP1
16 mg/l, 95% CI 14–17, P!0.001 and IFG/IFGCIGT:
f-IGFBP1 27 mg/l, 95% CI 24–31, P!0.001; 2-h
IGFBP1 14 mg/l, 95% CI 13–16, P!0.001) and similar
to the values seen in women developing diabetes
mellitus (PZ0.095, one-way ANOVA). Unlike the
women developing diabetes, however, those who were
to develop IGT or IFG/IFGCIGT had IGFBP1 levels that
were similarly suppressed in response to glucose
challenge, compared with controls (52%, 95% CI
50–54% and 52%, 95% CI 48–56% for IGT and
IFG/IFGCIGT respectively).
Factors predicting the development of
abnormal glucose regulation in women
Baseline variables were categorized into tertiles, and
ORs for the development of IGT, IFG or IFGCIGT and
diabetes were determined (Fig. 4 and Supplementary
Tables 3–5, see section on supplementary data given at
the end of this article). Individuals in the lowest tertile
for IGFBP1 at baseline had a 70-fold increased risk of
diabetes, and a 3- and 13-fold increased risk of IGT and
IFG/IFGCIGT respectively. Similar ORs were seen for
those in the highest tertiles for Wa
2HtR.
When f-IGFBP1 was log transformed and used as a
continuous variable, the OR for the risk of diabetes
was 5.69 (95% CI 2.37–13.65, P!0.001) for each
50% decrease in f-IGFBP1. Increasing values of
Wa
2HtR were also associated with the risk of diabetes
(P!0.001). When combined in a conditional logistic
regression analysis, Wa
2HtR remained independently
associated (PZ0.009), while f-IGFBP1
K1 was excluded
(PZ0.034).
Women developing abnormal glucose
regulation: variables at follow-up
Diabetes After the development of diabetes, f-IGFBP1
levels had increased by 22% (95% CI 6–41) in contrast
to a fall in the matched control group (K11%, 95% CI
K22–1; PZ0.001, cases versus controls). The increase
in f-IGFBP1 was observed despite increases in insulin
values that were not signiﬁcantly different to the
matched controls (61%, 95% CI 43–81 vs 38%, 95%
Table 1 Data for all control subjects: women at baseline, and men and women at follow-up.
Women (nZ240) Men (nZ355)
Baseline Follow-up
a Follow-up
a
Variables Mean (95% CI) Mean (95% CI) P value
b Mean (95% CI) P value
c
Age (years) 49.1 (48.6–49.7) 57.3 (56.8–57.9) !0.001 57.7 (57.2–58.2) 0.360
Height (m) 1.67 (1.66–1.67) 1.66 (1.65–1.66) !0.001 1.79 (1.78–1.79) !0.001
Weight (kg) 68.5 (67.2–69.8) 70.3 (68.9–71.7) !0.001 85.9 (84.7–87.2) !0.001
BMI (kg/m
2) 24.7 (24.2–25.1) 25.6 (25.1–26.1) !0.001 26.9 (26.5–27.2) !0.001
Waist (cm) 79 (78–80) 84 (82–85) !0.001 94 (93–953) !0.001
Hip (cm) 100 (99–101) 99 (98–100) 0.132 102 (102–103) !0.001
Waist/hip 0.79 (0.79–0.80) 0.84 (0.84–0.85) !0.001 0.92 (0.92–0.93) !0.001
Wa
2HtR
d 3.71 (3.61–3.81) 4.17 (4.05–4.29) !0.001 4.94 (4.85–5.03) !0.001
IGF1 (mg/l)
d 170 (164–177) 153 (147–159) !0.001 165 (160–170) 0.003
Systolic BP (mmHg) 120 (118–122) 133 (131–135) !0.001 135 (133–136) 0.304
Diastolic BP (mmHg) 74 (73–76) 82 (81–83) !0.001 83 (82–84) 0.424
Glucose (mmol/l)
0 h 4.7 (4.6–4.7) 4.9 (4.8–4.9) !0.001 5.0 (5.0–5.1) !0.001
2 h 4.5 (4.4–4.7) 4.8 (4.7–4.9) !0.001 5.0 (4.9–5.2) 0.019
Insulin (pmol/l)
d
0 h 60 (57–63) 83 (79–87) !0.001 89 (85–93) 0.035
2 h 198 (186–211) 273 (256–291) !0.001 277 (261–295) 0.702
IGFBP1 (mg/l)
d
0 h 41 (39–44) 38 (36–41) 0.009 19 (18–20) !0.001
2 h 20 (19–22) 19 (18–21) 0.040 10 (9–10) !0.001
2 h/0 h (%) 49 (48–51) 50 (49–52) 0.415 50 (48–52) 0.882
Obesity frequency
e 8% 12% 18%
FHD frequency 70% 78% 69%
Menstruating
f 67% 12%
aFollow-up 8 years for women and 10 years for men.
bPaired t-test.
cUnpaired t-test, men versus women.
dGeometric mean.
eAccording to WHO criteria (BMIR30).
fSelf-reported regular or irregular bleeding.
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www.eje-online.orgCI 24–55, PZ0.065, unpaired t-test). The regression
line of f-IGFBP1 on f-insulin shifted upwards to meet the
line for matched controls (Fig. 2b), and women with
diabetes at follow-up had on average 64% higher
f-IGFBP1 in relation to insulin, compared to baseline
levels (P!0.001). In the control group, the decrease in
IGFBP1 was related to the increase in insulin concen-
trations with time (Fig. 5a), while in the diabetes group,
this relationship between the change in f-IGFBP1 and
f-insulin was not observed. The change in IGFBP1 was
inversely correlated to the change in IGF1 in the group
developing diabetes but not in the controls (Fig. 5b).
At follow-up, the ability of a glucose challenge to
suppress IGFBP1 was not different to controls (Table 2
and Fig. 2d).
There was a tendency to a greater weight increase in
the women developing diabetes compared to matched
controls (5.0 kg, 95% CI 2.8–7.3 vs 1.9 kg, 95% CI 0.3–
3.4, PZ0.022), and there was a greater increase in the
Wa
2HtR (0.86, 95% CI 0.63–1.09 vs 0.47, 95% CI
0.28–0.65, PZ0.009). The increase in Wa
2HtRand the
Wa
2HtR value at baseline were associated with less
suppression of IGFBP1 after an oral glucose load at
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percentage of the fasting values, is related to the fasting (f)-IGFBP1
in women at baseline, 8 years before the development of diabetes
(a), tothe increase in waistmeasurement (Wa
2HtR) over 8 years (b)
and to the baseline Wa
2HtR (c). The individuals developing
diabetes (nZ60) are represented by the solid circles and
unbroken regression lines, and are compared to their matched
controls, whichare represented by the open circles. The vertical line
represents the cut-off value of the highest tertile for Wa
2HtR (c).
Correlation coefﬁcients: (a) controls: rZK0.30, PZ0.018;
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the individuals in the highest tertile for Wa
2HtR and
with %40% suppression of IGFBP1 developed diabetes
within 8 years (nZ19), and all but one individual in the
highest tertile had %50% suppression (nZ26).
IFG and/or IGT Fasting IGFBP1 did not change over
the 8 years in any of these groups (IGT: 29 mg/l, 95% CI
26–32, PZ0.358 compared to baseline and IFG or
IFGCIGT: 25 mg/l, 22–28, PZ0.135; Supplementary
Tables 1 and 2), while the 2-h IGFBP1 fell in those with
IFGorIFGCIGT(IGT:14 mg/l,95%CI13–15,PZ0.022
compared with baseline and IFG or IFGCIGT: 12 mg/l,
11–13, P!0.004). Fasting and 2-h values remained
lower at follow-up compared to matched controls in all
groups (P!0.001).
Gender differences
We have previously reported the baseline variables for
men in SDPP trial who developed abnormal glucose
regulation (6). Here, we present the follow-up data for
the men with diabetes in order to compare them with
women of the same age. Women with NGT at baseline
and at follow-up had lower values of waist and weight
measurements compared with men (Table 1). Control
women,however,hadagreaterincreaseinWa
2HtRover
an 8-year period (12%, 95% CI 10–14) compared with
control men of similar age over the preceding 10 years
(6%, 95% CI 4–8, P!0.001, unpaired t-test). Women
and men who developed diabetes in the preceding 8 or
10yearshadwaistmeasurementsthatwerenotdifferent
at follow-up (Table 2). In these women, the Wa
2HtR
measurement was 38% higher than their controls,
while men had measurements that were 20% higher
than their control group. More women developing
diabetes met the WHO deﬁnition of obesity (BMIR30)
compared with men at baseline and at follow-up.
Women had higher f-IGFBP1 and 2-h IGFBP1 levels
than men, in individuals with NGT (Table 1), in those
developing type 2 diabetes (Table 2), in IGT (f-IGFBP1
29 mg/l, 95% CI 26–32 vs 16 mg/l, 95% CI 14–18 for
women and men respectively at follow-up, P!0.001;
2-h IGFBP1 14 mg/l, 95% CI 13–15 vs 8 mg/l, 95% CI
7–9, P!0.001) and in IFG or IFGCIGT (f-IGFBP1
25 mg/l, 95% CI 22–28 vs 14 mg/l, 95% CI 13–16 for
women and men respectively at follow-up, P!0.001;
2-h IGFBP1 12 mg/l, 11–13 vs 7 mg/l, 95% CI 6–8,
P!0.001). The higher f-IGFBP1 levels were seen
despite similar f-insulin values compared with men.
Discussion
In this population-based prospective study of women,
low fasting IGFBP1 concentrations predicted the
development of abnormal glucose regulation 8 years
later. Women who later developed diabetes had levels of
fasting IGFBP1 that were lower than expected for the
fasting insulin values, and were associated with
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Women who developed diabetes were more likely to be
obese than men. However, similar to men, IGFBP1 levels
increased during the development of diabetes in women.
The design of the case–control study resulted in a
majority of subjects with a FHD. The control group of
men and women was matched for FHD, as well as
gender and age. Although the women and men
examined at the end of the study period were of similar
age, the duration of follow-up was different. We have
taken these limitations into account when examining
gender differences in this population. Thus, our
observations are in a Swedish population with high
social and genetic predisposition to diabetes who
developed abnormal glucose regulation within 8–10
years of having had NGT.
IGFBP1 concentrations were higher in women
compared to men of the same age, conﬁrming
observations in previous studies (19). The mechanism
underlying the gender difference in IGFBP1 in humans
is yet to be elucidated. In postmenopausal women, oral
estrogens increase IGFBP1 concentrations (20, 21).
This effect of estrogen appears to be independent of
insulin (22, 23). Administration of testosterone to
ageing men has no effect on circulating IGFBP1 levels
(24). In this study, we have found that the circulating
concentrations of insulin, the most important regulator
of IGFBP1, were similar in women and men of the same
age, suggesting that a difference in hepatic insulin
sensitivity and/or the presence of other regulators of
IGFBP1 is responsible for the gender difference.
An inverse relationship between fasting IGFBP1 and
insulin was seen in the normal women, as previously
observed in men from this population (6) and in other
studies of healthy individuals (25, 26).I nw o m e n
developing diabetes, there was a similar inverse
relationship between IGFBP1 and insulin at baseline.
These women were relatively obese, and this preserved
relationship has previously been reported in obesity (27,
28).L i k et h em e n ,t h ei n v e r s er e l a t i o n s h i pw a s
maintained in women after the development of diabetes,
buttheregressionlineshiftedupwards,consistentwitha
decrease inhepatic insulin sensitivityor reduced hepatic
insulin extraction (29). The regression line in women at
follow-up was not different from the matched control
group.Inthe men,however,thelevelsofIGFBP1relative
to the fasting insulin concentrations were above those of
their age-matched controls at follow-up (6).
The observation that the women who developed
diabetes had fasting IGFBP1 levels that were lowrelative
to insulin concentrations is a novel one. While it is
possible that this represents higher hepatic insulin
sensitivity in the fasted state, we have recently shown
that, in non-diabetic women and men with similar waist
measurements, fasting IGFBP1 levels correlated with
hepatic insulin sensitivity during a euglycaemic–hyper-
insulinaemic clamp (30). This raises the question of a
novel inhibitor of IGFBP1 production in the pre-diabetic
state in women. We speculate that adipose tissue could
be a source of that inhibitor.
Likethe studyinmen, IGF1 levelsinwomenwholater
developed diabetes were similar to controls, matched for
age and FHD, and did not predict the development of
abnormal glucose regulation. This lack of association
with IGF1 was also seen in another prospective study in
Sweden, in which low IGFBP1 predicted IGT and type 2
diabetes (31). However, we did observe an inverse
relationship between the increase in IGFBP1 and the
fall in IGF1 valuesafter the development of diabetes. The
causeofthisphenomenon isunknownbutwasalsoseen
in our previous study in men (6).
Obesity plays a very important role in the develop-
ment of abnormal glucose regulation in middle-aged
women (7, 8), and much of the epidemic of diabetes and
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to an increased prevalence of obesity (32, 33). A recent
meta-analysis has identiﬁed waist-to-height ratio as the
best discriminator of diabetes, hypertension and dysli-
pidaemia, over BMI (34). We have previously used
Wa
2HtR as measurement that takes into account the
dependence of waist on height in men (6).W en o wﬁ n d
that this measurement is appropriate for women in the
same population, although the reference range is lower
than that of men. There were marked increases in
Wa
2HtR in all of the women during the time of the study
regardless of glucose tolerance status, greater than
those seen in the men over a longer follow-up period.
This rapid development of central adiposity was not
surprising since many of the women were experiencing
menopause during the time of the study. Strategies that
address the problem of weight gain are crucial in the
prevention of diabetes. We observed that the women
with impaired IGFBP1 suppression after an oral glucose
load had the greatest increase in waist measurement.
We would recommend that Wa
2HtR might be used in
screening women for the riskof developing diabetes. The
ﬁnding of a low fasting IGFBP1 merely conﬁrms this
risk, but failure of IGFBP1 to suppress by more than
40% after an oral glucose load identiﬁes a group with
high risk of diabetes, which will be prone to an increase
in abdominal fat. Relevance of these observations to
other populations will be the focus of future studies.
Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.
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